The development of effective treatment against late-arising metastasis has become the centre of clinical attention and is one of the current challenges in cancer research. Presently, in most cancers including breast cancer, the development of metastasis is the critical clinical threshold. The goals in Metastatic Breast Cancer (MBC) management are primarily disease control and palliation of symptoms, combined with a good quality of life for the patient. The choice of therapy in the metastatic setting is now increasingly influenced by issues of cumulative toxicity and resistance.
Ovensa has generated first promising data on its drug nanotherapeutic candidate involving a common off-patent chemotherapeutic and its TRIOZAN™ delivery system. Ovensa is advancing its candidate in Metastatic Breast Cancer (MBC) in accordance with the FDA 505(b)(2) fast-track regulatory pathway. It has the possibility to provide a complete improvement of the drug profile allowing MBC patients to achieve significant overall survival and improved quality of life by reducing their side effects.
Treatment for glioblastoma multiform can be tricky due to the tumor cells resistance to conventional therapies, as well as the BBB, which often prevents therapies from reaching the targeted cells.
Ovensa is generating proof-of-concept data of nanoformulations enhancing the brain delivery of off-patent chemotherapeutics for the glioblastoma indication.
Currently, there is no drug approved to treat the core symptoms of autism spectrum disorder (ASD) such as communication difficulties, social impairment and repetitive and stereotyped patterns of behavior. The number of ASD patients is expected to grow in the next decade, resulting in an increased usage of drug therapy which in turn will drive the ASD therapeutics market.
Ovensa has generated first promising proof-of-concept data of a nanoformulation potentially enhancing the brain delivery of an off-patent molecule with positive behavioral effects in autism.
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder affecting elderly people worldwide, and is mainly characterized by two major pathological hallmarks of the AD brain: extracellular plaques, containing various forms of amyloid-β protein (Aβ), and intracellular neurofibrillary tangles (NFTs), composed of hyper-phosphorylated tau protein.
Ovensa is generating proof-of-concept data of nanoformulations enhancing the brain delivery of off-patent molecules with anti- Aβ and anti-tau effects for the AD indication.
Antibiotic resistance is recognized as a global health crisis. People become infected each year with bacteria that are resistant to antibiotics and many die each year as a direct result of these infections. From that, Methicillin-Resistant Staphylococcus aureus strain (MRSA), Vancomycin-Resistant Enterococcus (VRE), Vancomycin-Resistant Staphylococcus aureus (VRSA), Clostridium difficile, and Gram-negative bacteria are infections that need urgent new solutions in order to overcome the antibiotic resistance phenomena.
Ovensa has generated first promising proof-of-concept data on TRIOZAN excipient and a nanoformulation enhancing the effectiveness of an off-patent antibiotic molecule against resistant strains for the MRSA and VRE indications.